RF pain device developer Relievant completes $30mm Series D financing

New Enterprise Associates has led a $30mm Series D round for Relievant Medsystems Inc. (radiofrequency nerve ablation devices). Returning shareholders Canaan Partners, Emergent Medical Partners, Morgenthaler Ventures, and Onset Ventures also joined. The funding will support Relievant’s recently initiated surgical multi-center assessment of RF ablation for the treatment of vertebrogenic back pain (SMART) trial, which will evaluate the Intracept system in chronic axial low back pain. The minimally invasive probe delivers radiofrequency ablation to prevent pain signals from being transmitted by the basivertebral nerve.